

## YOUNG & EMERGING HEALTHCARE BUSINESSES - DELIVERING THE FUTURE

IN ASSOCIATION WITH GLAXOSMITHKLINE  
SUPPORTED BY TECHNOLOGY STRATEGY BOARD, STEVENAGE BIOSCIENCE CATALYST

*Draft programme (subject to change)*

**09:00 – 10:00 Registration, tea and coffee**

**10:00 – 10:10 Welcome**

Malcolm Skingle, Director, Academic Liaison – GlaxoSmithKline, PraxisUnico Board member

**Spinout company formation and finance - expert talks:**

**10:10 – 10:30** What makes a fundable company - David Philips, Partner – SR One

**10:30 – 10:50** Experiences of starting up a biotech company - Simon Tate, Chief Scientific Officer - Convergence Pharmaceuticals

**10:50 – 11:10** The pain of setting up - Jeff Errington, Director of the Institute for Cell and Molecular Biosciences - Newcastle University

**11:10 – 11:30** Invention for Innovation (i4i) and Health Innovation Challenge Fund (HICF) - Martin Hunt, Programme Director; Martin Anyim, Assistant Director; Simon Bradshaw, Assistant Director – NIHR

**11:30 – 12:00 Tea/coffee**

**12:00 – 12:20** Engaging with Technology Strategy Board programmes- Zahid Latif, Head of Healthcare – Technology Strategy Board

**12:20 – 12:40** R&D tax credits - Colin Hailey, Partner - Confluence Tax

**12:40 – 13:00** Stevenage Bioscience Catalyst, open innovation and new ways of working across the interfaces - Martino Picardo, Chief Executive Officer - Stevenage Bioscience Catalyst

**13:00 – 14:00 Networking lunch**

**14:00 – 15.00 Panel session – ‘Enter CVC – is there finally enough quality funding for quality ventures?’**

*Corporate Venture Capital (CVC) now accounts for around a quarter of investment (and rising) in healthcare ventures. Early reservations about taking CVC have largely dispelled and syndicates with independent venture capital (IVC) are now common. Does this now mean that there is finally enough capital to go around?*

Chair - Jeff Skinner, Executive Director, Deloitte Institute for Innovation and Entrepreneurship, London Business School; Training Committee – PraxisUnico

Panel - Tim Edwards - Cellzome, BioIndustry Association, ProtAffin AG  
Clive Holloway - Apposite Capital  
David Phillips –SR One  
Andy Sandham - Bicycle Therapeutics, NeurAxon, Kymab, PBC

**15:00 – 15.30 Tea /coffee**

**15:30 – 16.15 Keynote speech and Q&A session – Ian Tomlinson, Senior Vice President, Head of Biopharmaceuticals R&D and Worldwide Business Development -GlaxoSmithKline**

**16:15 – 16.30 Event round up and closing remarks - Douglas Roberston, Director of Research and Enterprise – Newcastle University, Chair - PraxisUnico**

**16:30 – 18:00 Stevenage BioScience Catalyst - drinks reception and tours of the incubator facility**